Q-omics provides the consensus-scored ZDHHC23 profile across patient tissues and cancer cell-line models. ZDHHC23 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZDHHC23 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, ZDHHC23 RNA expression shows 20,559 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where ZDHHC23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC23 survival associations across molecular data types. ZDHHC23 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC23 RNA expression–survival associations across cancer types. High ZDHHC23 expression shows unfavorable associations in UCEC, UVM, LGG and ACC, but favorable associations in HNSC and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZDHHC23 RNA expression.
This table summarizes ZDHHC23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZDHHC23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC23 shows lower tumor expression in THCA and KIRC and higher tumor expression in BLCA, STAD, HNSC and UCEC. The THCA box plot shows higher ZDHHC23 RNA expression in normal versus tumor tissue (log2 FC = −1.151, t-test p < 0.001).
This table shows molecular features associated with ZDHHC23 in patient tissues and cancer cell lines. In patient samples, ZDHHC23 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
